Infinatamab deruxtecan (I-DXd) demonstrated intracranial efficacy with acceptable safety in patients with extensive-stage small cell lung cancer (ES-SCLC) and baseline brain metastases, according to data from the primary analysis of the phase 2…
Infinatamab Deruxtecan Shows Encouraging CNS Activity in Extensive-Stage Small Cell Lung Cancer
